Total Toxicology Labs LLC

Total Toxicology Labs LLC was paid $1.92M by Medicaid between Jan 2018 and Sep 2023, across 42 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 38% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Michigan

Rank by total paid#26 of 108

Median peer was paid$588K

This provider vs. median3.3×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	6,642	$522K
2019	3,886	$299K
2020	5,145	$420K
2021	8,059	$437K
2022	7,975	$182K
2023	523	$58K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	38%	10,111	7,299	$725K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	30%	7,793	7,097	$572K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	23%	4,325	3,031	$433K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	2.0%	1,264	899	$39K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	1.5%	690	632	$29K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	308	293	$19K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	394	337	$12K
80361		<1%	69	59	$9K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	235	220	$7K
80356		<1%	71	61	$5K
81002		<1%	3,920	1,519	$5K
87481		<1%	105	80	$4K

30 more codes

80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	130	$4K
80324		<1%	72	$3K
80353		<1%	71	$2K
80354		<1%	71	$2K
80366		<1%	69	$2K
80373		<1%	69	$2K
80369		<1%	69	$2K
80359		<1%	71	$2K
80345		<1%	69	$2K
80362		<1%	69	$2K
80349		<1%	71	$2K
80372		<1%	69	$2K
80348		<1%	71	$2K
80346		<1%	72	$2K
80365		<1%	74	$2K
80358		<1%	71	$2K
80360		<1%	63	$2K
87529		<1%	135	$2K
80355		<1%	63	$2K
87581		<1%	201	$2K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	201	$2K
87511		<1%	192	$1K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	191	$1K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	124	$1K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	96	$981.02
87640		<1%	108	$810.67
83992		<1%	67	$767.32
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	66	$748.62
87653		<1%	98	$723.52
80320		0%	152	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBLUTH, MARTIN (DIRECTOR)